Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche’s Tecentriq

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES-SCLC).

Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone with used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo, Jazz said Tuesday.